

**MEDICAL LABORATORY**

**EVALUATION**

**PARTICIPANT SUMMARY**

**2 • 0 • 1 • 7**

Immunology  
2017 MLE-M1

ACP | Medical Laboratory  
Evaluation 

Total Commitment to Education and Service  
Provided by ACP, Inc.

# Table of Contents

Evaluation Criteria.....	3
<b>Immunology</b>	
<b>Infectious Mononucleosis</b> .....	<b>4</b>
<b>Rheumatoid Factor</b> .....	<b>6</b>
Qualitative .....	6
Quantitative (Titer).....	7
Quantitative (IU) .....	8
<b>Anti-Streptolysin O (ASO)</b> .....	<b>8</b>
<b>Complement C3</b> .....	<b>9</b>
<b>Complement C4</b> .....	<b>9</b>
<b>IgA</b> .....	<b>10</b>
<b>IgG</b> .....	<b>10</b>
<b>IgM</b> .....	<b>11</b>
<b>C-Reactive Protein, Regular</b> .....	<b>11</b>
Qualitative .....	11
Quantitative .....	11
<b>C-Reactive Protein, High Sensitivity</b> .....	<b>12</b>
<b>Antinuclear Antibody</b> .....	<b>12</b>
Qualitative .....	12
Quantitative (Titer).....	13
<b>Anti-dsDNA</b> .....	<b>14</b>
<b>Anti-RNP</b> .....	<b>14</b>
<b>Anti-RNP/Sm</b> .....	<b>15</b>
<b>Anti-SSA</b> .....	<b>15</b>
<b>Anti-SSB</b> .....	<b>15</b>
<b>Anti-SSA/SSB</b> .....	<b>16</b>
<b>Anti-Sm</b> .....	<b>16</b>
<b>Rubella</b> .....	<b>17</b>
Qualitative .....	17
Quantitative .....	17
<b>Anti-HIV</b> .....	<b>17</b>
<b>Allergen Specific IgE Antibodies</b> .....	<b>18</b>
<b>Total IgE</b> .....	<b>20</b>
<b>VDRL Slide</b> .....	<b>20</b>
<b>Syphilis Serology</b> .....	<b>21</b>
Qualitative: Treponema pallidum antibodies .....	21
Qualitative: RPR.....	21
Quantitative: RPR (Titer) .....	22
<b>H. pylori Antibody Detection</b> .....	<b>23</b>
<b>Mycoplasma Antibody</b> .....	<b>23</b>
<b>Viral Markers</b> .....	<b>24</b>
Anti-HBc (IgM).....	24
Anti-HBc (Total/IgG) .....	24
Anti-HIV.....	25
Anti-HAV (IgM) .....	25
Anti-HAV (Total/IgG).....	26
HBeAg.....	26
Anti-HBs .....	26
HBsAg.....	27
Anti-HCV .....	27

## Evaluation Criteria

The evaluation criteria used in the MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

### Qualitative

For qualitative procedures, evaluation is based on participant or referee consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Anti-dsDNA	80% Participant Consensus
Anti-HIV	80% Participant Consensus
Antinuclear Antibody (ANA)	80% Participant Consensus
Anti-RNP	80% Participant Consensus
Anti-RNP/Sm	80% Participant Consensus
Anti-Sm	80% Participant Consensus
Anti-SSA	80% Participant Consensus
Anti-SSA/SSB	80% Participant Consensus
Anti-SSB	80% Participant Consensus
Anti-Streptolysin O (ASO)	80% Participant Consensus
C-Reactive Protein	80% Participant Consensus
Diagnostic Allergy	80% Participant Consensus
H. <i>pylori</i> Antibody Detection	80% Participant Consensus
Infectious Mononucleosis	80% Participant Consensus
Mycoplasma Antibody	80% Participant Consensus
Rheumatoid Factor	80% Participant Consensus
Rubella Antibody	80% Participant Consensus
Syphilis Serology	80% Participant Consensus
Viral Markers	80% Participant Consensus

### Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 10 or more laboratories. Acceptable performance is established based on a target value  $\pm$  the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on page 37 under the heading "Acceptable Ranges for Quantitative Results."

Antinuclear Antibody (ANA) Titer	Not Evaluated
Anti-Streptolysin O (ASO) Titer	Not Evaluated
Complement C3	$\pm$ 3 SD
Complement C4	$\pm$ 3 SD
C-Reactive Protein	$\pm$ 3 SD
High Sensitivity C-Reactive Protein	$\pm$ 3 SD
Rheumatoid Factor (International Units)	$\pm$ 2 SD
Rheumatoid Factor (Titer)	Not Evaluated
Rubella (International Units)	$\pm$ 3 SD
Total IgA	$\pm$ 3 SD
Total IgE	$\pm$ 3 SD
Total IgG	$\pm$ 25%
Total IgM	$\pm$ 3 SD

## Infectious Mononucleosis

<u>Method</u>	<u>Specimen IM-1</u>		<u>Specimen IM-2</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	196	192	4
Alere Clearview - moderate	-	3	3	-
Alere Clearview - waived	-	6	6	-
Alere Clearview Mono Plus II - moderate	-	1	1	-
Alere Clearview Mono Plus II - waived	-	6	6	-
ASI	-	1	1	-
Beckman Coulter ICON Mono - waived	-	9	9	-
BioStar Acceava Mono Test	-	2	2	-
BioStar Acceava Mono-whole bld	-	4	4	-
BTNX Rapid Response – moderate	-	1	1	-
Cardinal Health SP Brand	-	1	1	-
Cardinal Health SP Brand - waived	-	7	7	-
Consult Diagnostics	-	24	24	-
Fisher HealthCare Sure-Vue	-	7	7	-
Henry Schein OneStep+ - waived	-	12	10	2
LifeSign Status - waived	-	8	8	-
McKesson Medi-Lab Performance - waived	-	2	2	-
Other Moderate method	-	4	4	-
Other Waived method	-	15	15	-
Quidel QuickVue+	-	2	2	-
Quidel QuickVue+ - waived	-	11	10	1
Sekisui OSOM	-	4	4	-
Sekisui OSOM (waived)	-	62	62	-
Seradyn	-	1	1	-
Wampole ColorCard	-	1	-	1

## Infectious Mononucleosis

<u>Method</u>	<b>Specimen IM-3</b>		<b>Specimen IM-4</b>		<b>Specimen IM-5</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	60	-	-	60	60	-
Alere Clearview - moderate	2	-	-	2	2	-
Alere Clearview Mono Plus II - moderate	1	-	-	1	1	-
Alere Clearview Mono Plus II - waived	1	-	-	1	1	-
ASI	1	-	-	1	1	-
Beckman Coulter ICON Mono - waived	9	-	-	9	9	-
BioStar Aceava Mono-whole bld	2	-	-	2	2	-
BTNX Rapid Response – moderate	1	-	-	1	1	-
Cardinal Health SP Brand	1	-	-	1	1	-
Cardinal Health SP Brand - waived	1	-	-	1	1	-
Consult Diagnostics	9	-	-	9	9	-
Fisher HealthCare Sure-View	3	-	-	3	3	-
Henry Schein OneStep+ - waived	4	-	-	4	4	-
LifeSign Status - waived	1	-	-	1	1	-
Other Moderate method	4	-	-	4	4	-
Other Waived method	2	-	-	2	2	-
Quidel QuickVue+	2	-	-	2	2	-
Quidel QuickVue+ - waived	2	-	-	2	2	-
Sekisui OSOM	4	-	-	4	4	-
Sekisui OSOM (waived)	8	-	-	8	8	-
Seradyn	1	-	-	1	1	-
Wampole ColorCard	1	-	-	1	1	-

## Rheumatoid Factor—Qualitative

<b><u>Method</u></b>	<b>Specimen RF-1</b>		<b>Specimen RF-2</b>		<b>Specimen RF-3</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	38	-	1	37	33	5
Abbott Architect	1	-	-	1	1	-
ASI	9	-	1	8	8	1
Biokit Rheumajet	4	-	-	4	4	-
Diamedix	1	-	-	1	1	-
Fisher HealthCare Sure-View	4	-	-	4	4	-
Immunostics Inc.	2	-	-	2	2	-
INOVA Diagnostics	1	-	-	1	1	-
Teco Diagnostics	1	-	-	1	1	-
TheraTest	4	-	-	4	4	-
Wampole ColorCard	7	-	-	7	3	4
Wampole Rheumatex	3	-	-	3	3	-

<b><u>Method</u></b>	<b>Specimen RF-4</b>		<b>Specimen RF-5</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	37	1	3	35
Abbott Architect	1	-	-	1
ASI	9	-	2	7
Biokit Rheumajet	4	-	-	4
Diamedix	1	-	-	1
Fisher HealthCare Sure-View	4	-	-	4
Immunostics Inc.	1	1	1	1
INOVA Diagnostics	1	-	-	1
Teco Diagnostics	1	-	-	1
TheraTest	4	-	-	4
Wampole ColorCard	7	-	-	7
Wampole Rheumatex	3	-	-	3

**Rheumatoid Factor—Quantitative (Titer)**

<u>Specimen/Method</u>	<u>2/ 4</u>	<u>8/ 10</u>	<u>16/ 20</u>	<u>32/ 40</u>	<u>64/ 80</u>	<u>128/ 160</u>	<u>256/ 320</u>	<u>512/ 640</u>	<u>1024/ 1280</u>	<u>2048/ 2560</u>	<u>&gt;2560</u>	<u>N/A (Neg)</u>
<b>Specimen RF-1</b>												
ALL METHODS	-	-	2	1	1	-	-	-	-	-	-	-
ASI	-	-	-	-	1	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	-	-	2	-	-	-	-	-	-	-	-	-
Wampole ColorCard	-	-	-	1	-	-	-	-	-	-	-	-
<b>Specimen RF-2</b>												
ALL METHODS	-	-	-	-	-	-	-	-	-	-	-	4
ASI	-	-	-	-	-	-	-	-	-	-	-	1
Fisher HealthCare Sure-Vue	-	-	-	-	-	-	-	-	-	-	-	2
Wampole ColorCard	-	-	-	-	-	-	-	-	-	-	-	1
<b>Specimen RF-3</b>												
ALL METHODS	-	-	2	1	1	-	-	-	-	-	-	-
ASI	-	-	-	-	1	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	-	-	2	-	-	-	-	-	-	-	-	-
Wampole ColorCard	-	-	-	1	-	-	-	-	-	-	-	-
<b>Specimen RF-4</b>												
ALL METHODS	-	-	1	2	1	-	-	-	-	-	-	-
ASI	-	-	-	-	1	-	-	-	-	-	-	-
Fisher HealthCare Sure-Vue	-	-	-	2	-	-	-	-	-	-	-	-
Wampole ColorCard	-	-	1	-	-	-	-	-	-	-	-	-
<b>Specimen RF-5</b>												
ALL METHODS	-	-	-	-	-	-	-	-	-	-	-	4
ASI	-	-	-	-	-	-	-	-	-	-	-	1
Fisher HealthCare Sure-Vue	-	-	-	-	-	-	-	-	-	-	-	2
Wampole ColorCard	-	-	-	-	-	-	-	-	-	-	-	1

**Rheumatoid Factor—Quantitative (IU/mL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen RF-1</b>						
All Method	19	174.8	35.7	20.4	172	103 - 247
<b>Specimen RF-2</b>						
All Method	19	7.5	3.4	45.7	9	0 - 15
<b>Specimen RF-3</b>						
All Method	19	94.6	26.7	28.2	86	41 - 149
<b>Specimen RF-4</b>						
All Method	19	174.0	35.7	20.5	172	102 - 246
<b>Specimen RF-5</b>						
All Method	19	7.6	3.5	46.4	9	0 - 15

**Anti-Streptolysin O (ASO)—Qualitative**

<u>Method</u>	<b>Specimen AS-1</b>		<b>Specimen AS-2</b>		<b>Specimen AS-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	1	1	-	1	-
<u>Method</u>	<b>Specimen AS-4</b>		<b>Specimen AS-5</b>			
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>		
ALL METHODS	1	-	-	1		



**Complement C3 (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-1</b>						
All Method	15	94.2	2.7	2.9	95	86 - 103
<b>Specimen IMP-2</b>						
All Method	15	90.2	3.3	3.7	89	80 - 101
<b>Specimen IMP-3</b>						
All Method	15	119.7	4.4	3.7	120	106 - 133
<b>Specimen IMP-4</b>						
All Method	14	56.1	2.7	4.8	56	48 - 65
<b>Specimen IMP-5</b>						
All Method	14	142.5	7.2	5.1	146	120 - 165

**Complement C4 (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-1</b>						
All Method	15	18.3	0.9	4.8	18	15 - 21
<b>Specimen IMP-2</b>						
All Method	15	17.8	0.9	5.3	18	14 - 21
<b>Specimen IMP-3</b>						
All Method	15	23.7	1.2	5.2	24	19 - 28
<b>Specimen IMP-4</b>						
All Method	14	10.9	0.7	6.1	11	8 - 13
<b>Specimen IMP-5</b>						
All Method	14	28.9	1.9	6.6	29	23 - 35

**IgA (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-1</b>						
All Method	11	127.1	8.5	6.7	126	101 - 153
<b>Specimen IMP-2</b>						
All Method	11	132.6	6.6	5.0	132	112 - 153
<b>Specimen IMP-3</b>						
All Method	11	164.1	10.5	6.4	166	132 - 196
<b>Specimen IMP-4</b>						
All Method	11	80.6	5.7	7.1	82	63 - 98
<b>Specimen IMP-5</b>						
All Method	11	495.2	38.4	7.8	491	379 - 611

**IgG (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-1</b>						
All Method	11	635.6	55.6	8.7	626	476 - 795
<b>Specimen IMP-2</b>						
All Method	11	1833.0	138.8	7.6	1821	1374 - 2292
<b>Specimen IMP-3</b>						
All Method	11	831.9	64.7	7.8	834	623 - 1040
<b>Specimen IMP-4</b>						
All Method	11	396.5	36.6	9.2	384	297 - 496
<b>Specimen IMP-5</b>						
All Method	11	976.5	89.6	9.2	987	732 - 1221

**IgM (mg/dL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen IMP-1</b>						
All Method	11	456.5	65.8	14.4	475	258 - 654
<b>Specimen IMP-2</b>						
All Method	11	59.5	7.3	12.3	56	37 - 82
<b>Specimen IMP-3</b>						
All Method	11	77.8	5.3	6.8	78	62 - 94
<b>Specimen IMP-4</b>						
All Method	11	36.6	1.5	4.1	36	32 - 42
<b>Specimen IMP-5</b>						
All Method	11	93.1	6.3	6.8	93	74 - 113

**C-Reactive Protein—Qualitative, Regular**

<u>Method</u>	<u>Specimen CR-1</u>		<u>Specimen CR-2</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	10	-	10	-
Fisher HealthCare Sure-Vue	8	-	8	-
Siemens Dimension/AR/ES/RxL/Xpand	2	-	2	-

**C-Reactive Protein—Quantitative (mg/dL), Regular**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen CR-1</b>						
mg/dL - units						
All Immunology Methods	21	3.268	0.498	15.2	3.30	1.77 - 4.77
mg/L - units						
All Immunology Methods	13	30.160	5.088	16.9	28.20	14.89 - 45.43
<b>Specimen CR-2</b>						
mg/dL - units						
All Immunology Methods	21	7.117	0.655	9.2	7.30	5.15 - 9.09
mg/L - units						
All Immunology Methods	15	68.099	9.073	13.3	64.70	40.88 - 95.32

**C-Reactive Protein—Quantitative (mg/dL), High Sensitivity**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen HCR-1</b>						
All Method	33	10.953	1.092	10.0	11.02	7.67 - 14.23
Beckman AU	10	10.391	1.213	11.7	10.89	6.75 - 14.03
<b>Specimen HCR-2</b>						
All Method	34	0.823	0.270	32.8	0.90	0.01 - 1.64
Beckman AU	10	1.219	1.346	110.4	0.90	0.00 - 5.26

**Antinuclear Antibody (ANA) - Qualitative**

<u>Method</u>	<u>Specimen AE-1</u>		<u>Specimen AE-2</u>		<u>Specimen AE-3</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	12	-	1	11	11	1
ASI	2	-	-	2	2	-
Bio-Rad	1	-	-	1	1	-
Immuno Concepts	3	-	1	2	3	-
INOVA Diagnostics	2	-	-	2	1	1
TheraTest	2	-	-	2	2	-
Vernostics	1	-	-	1	1	-

<u>Method</u>	<u>Specimen AE-4</u>		<u>Specimen AE-5</u>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	12	-	2	10
ASI	2	-	-	2
Bio-Rad	1	-	-	1
Immuno Concepts	3	-	1	2
INOVA Diagnostics	2	-	-	2
TheraTest	2	-	-	2
Vernostics	1	-	1	-

**Antinuclear Antibody (ANA)—Quantitative (Titer)**

<u>Specimen/Method</u>	<u>8/ 10</u>	<u>16/ 20</u>	<u>32/ 40</u>	<u>64/ 80</u>	<u>128/ 160</u>	<u>256/ 320</u>	<u>512/ 640</u>	<u>&gt;640</u>	<u>1024/ 1280</u>	<u>2048/ 2560</u>	<u>≥2560</u>	<u>N/A (Neg)</u>
<b>Specimen AE-1</b>												
ALL METHODS	-	-	-	-	-	1	-	2	1	-	-	-
Bio-Rad	-	-	-	-	-	1	-	-	-	-	-	-
Immuno Concepts	-	-	-	-	-	-	-	1	1	-	-	-
INOVA Diagnostics	-	-	-	-	-	-	-	1	-	-	-	-
<b>Specimen AE-2</b>												
ALL METHODS	-	-	-	-	1	-	-	-	-	-	-	3
Bio-Rad	-	-	-	-	-	-	-	-	-	-	-	1
Immuno Concepts	-	-	-	-	1	-	-	-	-	-	-	1
INOVA Diagnostics	-	-	-	-	-	-	-	-	-	-	-	1
<b>Specimen AE-3</b>												
ALL METHODS	-	-	-	-	-	3	1	-	-	-	-	-
Bio-Rad	-	-	-	-	-	1	-	-	-	-	-	-
Immuno Concepts	-	-	-	-	-	1	1	-	-	-	-	-
INOVA Diagnostics	-	-	-	-	-	1	-	-	-	-	-	-
<b>Specimen AE-4</b>												
ALL METHODS	-	-	-	1	-	2	-	1	-	-	-	-
Bio-Rad	-	-	-	-	-	1	-	-	-	-	-	-
Immuno Concepts	-	-	-	1	-	-	-	1	-	-	-	-
INOVA Diagnostics	-	-	-	-	-	1	-	-	-	-	-	-
<b>Specimen AE-5</b>												
ALL METHODS	-	-	-	-	1	-	-	-	-	-	-	3
Bio-Rad	-	-	-	-	-	-	-	-	-	-	-	1
Immuno Concepts	-	-	-	-	1	-	-	-	-	-	-	1
INOVA Diagnostics	-	-	-	-	-	-	-	-	-	-	-	1

## Anti-dsDNA

<u>Method</u>	Specimen AE-1		Specimen AE-2		Specimen AE-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	6	-	1	5	6	-
Immuno Concepts	1	-	-	1	1	-
INOVA Diagnostics	1	-	-	1	1	-
TheraTest	4	-	1	3	4	-

<u>Method</u>	Specimen AE-4		Specimen AE-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	3	3	-	6
Immuno Concepts	1	-	-	1
INOVA Diagnostics	-	1	-	1
TheraTest	2	2	-	4

Specimen AE-4 is an ungraded challenge due to less than 80% participant consensus.

## Anti-RNP

<u>Method</u>	Specimen AE-1		Specimen AE-2		Specimen AE-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	1	-	1	-	1
Immuno Concepts	-	1	-	1	-	1

<u>Method</u>	Specimen AE-4		Specimen AE-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	1	-	1
Immuno Concepts	-	1	-	1

## Anti-RNP/Sm

<u>Method</u>	Specimen AE-1		Specimen AE-2		Specimen AE-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6	5	1
Immuno Concepts	-	1	-	1	-	1
INOVA Diagnostics	-	1	-	1	1	-
TheraTest	-	4	-	4	4	-

<u>Method</u>	Specimen AE-4		Specimen AE-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6
Immuno Concepts	-	1	-	1
INOVA Diagnostics	-	1	-	1
TheraTest	-	4	-	4

## Anti-SSA

<u>Method</u>	Specimen AE-1		Specimen AE-2		Specimen AE-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	6	-	1	5	6	-
Immuno Concepts	1	-	-	1	1	-
INOVA Diagnostics	1	-	-	1	1	-
TheraTest	4	-	1	3	4	-

<u>Method</u>	Specimen AE-4		Specimen AE-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	6	-	-	6
Immuno Concepts	1	-	-	1
INOVA Diagnostics	1	-	-	1
TheraTest	4	-	-	4

## Anti-SSB

<u>Method</u>	Specimen AE-1		Specimen AE-2		Specimen AE-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	5	1	-	6	-	6
Immuno Concepts	-	1	-	1	-	1
INOVA Diagnostics	1	-	-	1	-	1
TheraTest	4	-	-	4	-	4

<u>Method</u>	Specimen AE-4		Specimen AE-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	6	-	-	6
Immuno Concepts	1	-	-	1
INOVA Diagnostics	1	-	-	1
TheraTest	4	-	-	4

**Anti-SSA/SSB**

<u>Method</u>	Specimen AE-1		Specimen AE-2		Specimen AE-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	-	-	-	-	-
Immuno Concepts	-	-	-	-	-	-

<u>Method</u>	Specimen AE-4		Specimen AE-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	-	-	-
Immuno Concepts	-	-	-	-

**Anti-Sm**

<u>Method</u>	Specimen AE-1		Specimen AE-2		Specimen AE-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6	-	6
Immuno Concepts	-	1	-	1	-	1
INOVA Diagnostics	-	1	-	1	-	1
TheraTest	-	4	-	4	-	4

<u>Method</u>	Specimen AE-4		Specimen AE-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	6	-	6
Immuno Concepts	-	1	-	1
INOVA Diagnostics	-	1	-	1
TheraTest	-	4	-	4



**Rubella—Qualitative**

<u>Method</u>	Specimen RU-1		Specimen RU-2		Specimen RU-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	5	5	-	5	-
bioMerieux Vidas, Mini Vidas	-	1	1	-	1	-
DiaSorin	-	1	1	-	1	-
INOVA Diagnostics	-	1	1	-	1	-
Siemens ADVIA Centaur	-	2	2	-	2	-

<u>Method</u>	Specimen RU-4		Specimen RU-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	5	-	5
bioMerieux Vidas, Mini Vidas	-	1	-	1
DiaSorin	-	1	-	1
Roche cobas e 411	-	1	-	1
Siemens ADVIA Centaur	-	2	-	2

**Rubella—Quantitative (IU/mL)**

One lab reported results for Rubella – Quantitative (IU/mL). The vendor assay values for specimens RU-1 through RU-5 are: <10 IU/mL, 39.7 IU/mL, 39.7 IU/mL, <10 IU/mL and <10 IU/mL, respectively.

**Anti-HIV**

<u>Method</u>	Specimen HIV-1		Specimen HIV-2	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	59	58	1
Alere Clearview Complete HIV 1/2	-	9	9	-
Alere Clearview HIV1/2 STAT-PAK	-	6	6	-
Alere Determine HIV 1/2 Ag/Ab Combo	-	2	2	-
Chembio HIV 1/2 Assay - moderate	-	1	1	-
Orasure OraQuick Advance Rapid HIV-1/2 - moderate	-	1	1	-
Orasure OraQuick Advance Rapid HIV-1/2 - waived	-	22	21	1
Other Waived method	-	8	8	-
Trinity Biotech Uni-Gold - waived	-	10	10	-

<u>Method</u>	Specimen HIV-3		Specimen HIV-4		Specimen HIV-5	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	5	-	-	5	-	5
Chembio HIV 1/2 Assay - moderate	5	-	-	5	-	5

## Allergen Specific IgE Antibodies

### Specimen AL-1

<b>Method</b>	<b>Common (Short) Ragweed (w1) Allergen</b>								<b>Bermuda Grass (g2) Allergen</b>								
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>								
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6	
ALL METHODS	-	-	-	4	1	-	-	-	-	-	-	3	2	1	-	-	-
DPC-Standard Microplate	-	-	-	1	-	-	-	-	-	-	-	-	1	-	-	-	-
Hitachi CLA-1	-	-	-	1	1	-	-	-	-	-	-	3	-	1	-	-	-
Phadia UniCap 100 (% ref)	-	-	-	1	-	-	-	-	-	-	-	-	1	-	-	-	-
Phadia UniCap 100 (KU/L)	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-

  

<b>Method</b>	<b>Meadow, Kentucky Blue, June Grass (g8) Allergens</b>								<b>Maple (Box Elder) (t1) Allergen</b>							
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>							
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6
ALL METHODS	-	-	-	-	-	3	-	1	2	2	2	1	-	-	-	-
DPC-Standard Microplate	-	-	-	-	-	-	-	1	-	1	-	-	-	-	-	-
Hitachi CLA-1	-	-	-	-	-	1	-	-	2	1	1	-	-	-	-	-
Phadia UniCap 100 (% ref)	-	-	-	-	-	1	-	-	-	-	1	-	-	-	-	-
Phadia UniCap 100 (KU/L)	-	-	-	-	-	1	-	-	-	-	-	1	-	-	-	-

  

<b>Method</b>	<b>Mouse Urine Protein (e72) Allergen</b>								<b>Dog Dander (e5) Allergen</b>							
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>							
	0	0/1	1	2	3	4	5	6	0	0/1	1	2	3	4	5	6
ALL METHODS	-	-	-	-	-	-	-	-	-	-	-	-	1	1	4	-
DPC-Standard Microplate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hitachi CLA-1	-	-	-	-	-	-	-	-	-	-	-	-	-	4	-	-
Phadia UniCap 100 (% ref)	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
Phadia UniCap 100 (KU/L)	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-

  

<b>Method</b>	<b>Alternaria alternata (m6) Allergen</b>							
	<b>CLASS RESULT</b>							
	0	0/1	1	2	3	4	5	6
ALL METHODS	-	2	2	3	-	-	-	-
DPC-Standard Microplate	-	-	-	1	-	-	-	-
Hitachi CLA-1	-	2	2	-	-	-	-	-
Phadia UniCap 100 (% ref)	-	-	-	1	-	-	-	-
Phadia UniCap 100 (KU/L)	-	-	-	1	-	-	-	-

**Allergen Specific IgE Antibodies**

**Specimen AL-2**

<b><u>Method</u></b>	<b>English Plantain (w9) Allergen</b>								<b>Sweet Vernal Grass (g1) Allergen</b>							
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>							
	<b>0</b>	<b>0/1</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>0</b>	<b>0/1</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>
ALL METHODS	3	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-
DPC-Standard Microplate	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Hitachi CLA-1	3	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Phadia UniCap 100 (% ref)	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Phadia UniCap 100 (KU/L)	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
	<b>Perennial Rye (g5) Allergen</b>								<b>White Oak (t7) Allergen</b>							
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>							
	<b>0</b>	<b>0/1</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>0</b>	<b>0/1</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>
ALL METHODS	-	-	-	-	-	-	2	-	-	-	1	4	1	-	-	-
DPC-Standard Microplate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hitachi CLA-1	-	-	-	-	-	-	-	-	-	-	1	2	1	-	-	-
Phadia UniCap 100 (% ref)	-	-	-	-	-	-	1	-	-	-	-	1	-	-	-	-
Phadia UniCap 100 (KU/L)	-	-	-	-	-	-	1	-	-	-	-	1	-	-	-	-
	<b>Cockroach - German (i6) Allergen</b>								<b>House Dust Mite (D. pteronyssinus) (d1) Allergen</b>							
	<b>CLASS RESULT</b>								<b>CLASS RESULT</b>							
	<b>0</b>	<b>0/1</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>0</b>	<b>0/1</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>
ALL METHODS	-	2	1	-	-	-	-	-	-	-	-	4	1	1	-	-
DPC-Standard Microplate	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
Hitachi CLA-1	-	1	1	-	-	-	-	-	-	-	-	1	1	1	-	-
Phadia UniCap 100 (% ref)	-	1	-	-	-	-	-	-	-	-	-	1	-	-	-	-
Phadia UniCap 100 (KU/L)	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
	<b>Rat Urine Protein (e74) Allergen</b>															
	<b>CLASS RESULT</b>															
	<b>0</b>	<b>0/1</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>								
ALL METHODS	-	-	-	-	-	-	-	-								
DPC-Standard Microplate	-	-	-	-	-	-	-	-								
Hitachi CLA-1	-	-	-	-	-	-	-	-								
Phadia UniCap 100 (% ref)	-	-	-	-	-	-	-	-								
Phadia UniCap 100 (KU/L)	-	-	-	-	-	-	-	-								

**Total IgE—Quantitative (U/mL)**

<u>Specimen/Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Range</u>
<b>Specimen AL-1</b>						
All Method	5	237.3	5.8	2.4	234	220 - 255
<b>Specimen AL-2</b>						
All Method	5	384.7	13.9	3.6	381	343 - 427
<b>Specimen AL-3</b>						
All Method	5	67.3	3.8	5.6	69	55 - 79
<b>Specimen AL-4</b>						
All Method	5	19.3	1.2	6.0	20	15 - 23
<b>Specimen AL-5</b>						
All Method	5	20.0	2.0	10.0	20	14 - 26

**VDRL Slide**

<u>Method</u>	<b>Specimen SY-1</b>			<b>Specimen SY-2</b>		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	-	1	1	-	-
ASI	-	-	1	1	-	-
	<b>Specimen SY-3</b>			<b>Specimen SY-4</b>		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	1	-	-	-	-	1
ASI	1	-	-	-	-	1
	<b>Specimen SY-5</b>					
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>			
ALL METHODS	1	-	-			
ASI	1	-	-			

**Syphilis Serology—Qualitative: Treponema pallidum antibodies**

<b><u>Method</u></b>	<b>Specimen SY-1</b>		<b>Specimen SY-2</b>		<b>Specimen SY-3</b>	
	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>
ALL METHODS	-	9	9	-	9	-
diagnostics direct Syphilis Health Check	-	7	7	-	7	-
INOVA Diagnostics	-	1	1	-	1	-
Siemens ADVIA Centaur	-	1	1	-	1	-

<b><u>Method</u></b>	<b>Specimen SY-4</b>		<b>Specimen SY-5</b>	
	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>
ALL METHODS	-	9	9	-
diagnostics direct Syphilis Health Check	-	7	7	-
INOVA Diagnostics	-	1	1	-
Siemens ADVIA Centaur	-	1	1	-

**Syphilis Serology—Qualitative: RPR**

<b><u>Method</u></b>	<b>Specimen SY-1</b>		<b>Specimen SY-2</b>		<b>Specimen SY-3</b>	
	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>
ALL METHODS	-	15	15	-	15	-
ASI	-	5	5	-	5	-
Becton Dickinson diagnostics direct Syphilis Health Check	-	5	5	-	5	-
Fisher HealthCare Sure-View	-	1	1	-	1	-
Wampole Impact RPR	-	3	3	-	3	-
	-	1	1	-	1	-

<b><u>Method</u></b>	<b>Specimen SY-4</b>		<b>Specimen SY-5</b>	
	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>
ALL METHODS	-	15	15	-
ASI	-	5	5	-
Becton Dickinson diagnostics direct Syphilis Health Check	-	5	5	-
Fisher HealthCare Sure-View	-	1	1	-
Wampole Impact RPR	-	3	3	-
	-	1	1	-

**Syphilis Serology—Quantitative: RPR (Titer)**

<u>Specimen/Method</u>	<u>1:1</u>	<u>1:2</u>	<u>1:4</u>	<u>1:8</u>	<u>1:16</u>	<u>1:32</u>	<u>1:64</u>	<u>1:&gt;64</u>	<u>N/A (Neg)</u>
------------------------	------------	------------	------------	------------	-------------	-------------	-------------	-----------------	----------------------

**Specimen SY-1**

ALL METHODS	-	-	-	-	-	-	-	-	6
ASI	-	-	-	-	-	-	-	-	2
Becton Dickinson	-	-	-	-	-	-	-	-	4

**Specimen SY-2**

ALL METHODS	-	-	1	5	-	-	-	-	-
ASI	-	-	1	1	-	-	-	-	-
Becton Dickinson	-	-	-	4	-	-	-	-	-

**Specimen SY-3**

ALL METHODS	-	1	5	-	-	-	-	-	-
ASI	-	1	1	-	-	-	-	-	-
Becton Dickinson	-	-	4	-	-	-	-	-	-

**Specimen SY-4**

ALL METHODS	-	-	-	-	-	-	-	-	6
ASI	-	-	-	-	-	-	-	-	2
Becton Dickinson	-	-	-	-	-	-	-	-	4

**Specimen SY-5**

ALL METHODS	-	-	6	-	-	-	-	-	-
ASI	-	-	2	-	-	-	-	-	-
Becton Dickinson	-	-	4	-	-	-	-	-	-

## H. pylori Antibody Detection

<b><u>Method</u></b>	<b>Specimen HP-1</b>		<b>Specimen HP-2</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	-	67	65	2
Alere Clearview - moderate	-	5	5	-
Alfa Scientific Instant-View	-	1	1	-
Cardinal Health SP Brand	-	2	2	-
Consult Diagnostics	-	20	19	1
Fisher HealthCare Sure-View	-	2	2	-
Henry Schein OneStep+ - waived	-	11	11	-
Immunostics Inc.	-	1	1	-
McKesson Medi-Lab Performance - waived	-	1	1	-
Quidel QuickVue	-	21	21	-
SDI Biomed, Inc.	-	1	1	-
Sekisui OSOM	-	1	1	-

## Mycoplasma Antibody

<b><u>Method</u></b>	<b>Specimen MY-1</b>		<b>Specimen MY-2</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	-	2	2	-
Meridian ImmunoCard	-	2	2	-

**Viral Markers – Anti-HBc (IgM)**

<u>Method</u>	<u>Specimen VM-1</u>			<u>Specimen VM-2</u>			<u>Specimen VM-3</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	1	3	-	4	-	-	4	-
Siemens ADVIA									
Centaur	-	-	3	-	3	-	-	3	-
VITROS 5600	-	1	-	-	1	-	-	1	-

<u>Method</u>	<u>Specimen VM-4</u>			<u>Specimen VM-5</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	4	-	-	4	-
Siemens ADVIA						
Centaur	-	3	-	-	3	-
VITROS 5600	-	1	-	-	1	-

**Viral Markers – Anti-HBc (Total/IgG)**

<u>Method</u>	<u>Specimen VM-1</u>			<u>Specimen VM-2</u>			<u>Specimen VM-3</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	2	-	-	2	-	-	-	2	-
Siemens ADVIA									
Centaur	2	-	-	2	-	-	-	2	-

<u>Method</u>	<u>Specimen VM-4</u>			<u>Specimen VM-5</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	1	-	1	2	-	-
Siemens ADVIA						
Centaur	1	-	1	2	-	-



**Viral Markers – Anti-HIV**

<b><u>Method</u></b>	<b>Specimen VM-1</b>			<b>Specimen VM-2</b>			<b>Specimen VM-3</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	5	-	-	5	-	5	-	-
Abbott Architect	-	2	-	-	2	-	2	-	-
Siemens ADVIA									
Centaur	-	2	-	-	2	-	2	-	-

<b><u>Method</u></b>	<b>Specimen VM-4</b>			<b>Specimen VM-5</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	5	-	-	5	-
Abbott Architect	-	2	-	-	2	-
Siemens ADVIA						
Centaur	-	2	-	-	2	-

**Viral Markers – Anti-HAV (IgM)**

<b><u>Method</u></b>	<b>Specimen VM-1</b>			<b>Specimen VM-2</b>			<b>Specimen VM-3</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	4	-	-	4	-	-	4	-
Siemens ADVIA									
Centaur	-	3	-	-	3	-	-	3	-
VITROS 5600	-	1	-	-	1	-	-	1	-

<b><u>Method</u></b>	<b>Specimen VM-4</b>			<b>Specimen VM-5</b>		
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Equivocal</u></b>
ALL METHODS	-	4	-	-	4	-
Siemens ADVIA						
Centaur	-	3	-	-	3	-
VITROS 5600	-	1	-	-	1	-

**Viral Markers – Anti-HAV (Total/IgG)**

<u>Method</u>	<u>Specimen VM-1</u>			<u>Specimen VM-2</u>			<u>Specimen VM-3</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	3	-	-	3	-	3	-	-
Siemens ADVIA									
Centaur	-	3	-	-	3	-	3	-	-

  

<u>Method</u>	<u>Specimen VM-4</u>			<u>Specimen VM-5</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	3	-	-	3	-	-
Siemens ADVIA						
Centaur	3	-	-	3	-	-

**Viral Markers – HBeAg**

One participant reported results for HBeAg. The vendor assay values for specimens VM-1 through VM-5 are: Positive, Negative, Negative, Negative and Positive, respectively.

**Viral Markers – Anti-HBs**

<u>Method</u>	<u>Specimen VM-1</u>			<u>Specimen VM-2</u>			<u>Specimen VM-3</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	5	-	5	-	-	5	-	-
Siemens ADVIA									
Centaur	-	5	-	5	-	-	5	-	-

  

<u>Method</u>	<u>Specimen VM-4</u>			<u>Specimen VM-5</u>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	5	-	-	-	5	-
Siemens ADVIA						
Centaur	5	-	-	-	5	-

**Viral Markers – HBsAg**

<u>Method</u>	<b>Specimen VM-1</b>			<b>Specimen VM-2</b>			<b>Specimen VM-3</b>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	7	-	-	-	7	-	-	7	-
Abbott Architect	1	-	-	-	1	-	-	1	-
Siemens ADVIA									
Centaur	4	-	-	-	4	-	-	4	-
Siemens									
Immolute/1000	1	-	-	-	1	-	-	1	-
VITROS 5600	1	-	-	-	1	-	-	1	-

<u>Method</u>	<b>Specimen VM-4</b>			<b>Specimen VM-5</b>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	7	-	7	-	-
Abbott Architect	-	1	-	1	-	-
Siemens ADVIA						
Centaur	-	4	-	4	-	-
Siemens						
Immolute/1000	-	1	-	1	-	-
VITROS 5600	-	1	-	1	-	-

**Viral Markers – Anti-HCV**

<u>Method</u>	<b>Specimen VM-1</b>			<b>Specimen VM-2</b>			<b>Specimen VM-3</b>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	9	-	-	9	-	-	9	-
Abbott Architect	-	2	-	-	2	-	-	2	-
OraSure OraQuick									
HCV	-	1	-	-	1	-	-	1	-
Siemens ADVIA									
Centaur	-	5	-	-	5	-	-	5	-
VITROS 5600	-	1	-	-	1	-	-	1	-

<u>Method</u>	<b>Specimen VM-4</b>			<b>Specimen VM-5</b>		
	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>	<u>Positive</u>	<u>Negative</u>	<u>Equivocal</u>
ALL METHODS	-	9	-	-	9	-
Abbott Architect	-	2	-	-	2	-
OraSure OraQuick						
HCV	-	1	-	-	1	-
Siemens ADVIA						
Centaur	-	5	-	-	5	-
VITROS 5600	-	1	-	-	1	-

**Medical Laboratory Evaluation**

25 Massachusetts Ave NW Ste 700

Washington, DC 20001-7401

800-338-2746 • 202-261-4500 • Fax: 202-835-0440

[www.acponline.org/mle](http://www.acponline.org/mle)